RHY.AX ASX
Rhythm Biosciences Limited
1W: -2.4%
1M: -5.9%
3M: -14.0%
YTD: -64.4%
1Y: -12.1%
3Y: -78.2%
5Y: -91.8%
A$0.08 ($0.05)
-0.00 (-1.25%)
Weekly Expected Move ±5.1%
A$0
A$0
A$0
A$0
A$0
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Smart Money Score
No convergence signal
Key Statistics
Market CapA$28.3M ($19.7M)
52W Range0.075-0.28
Volume15,558
Avg Volume272,840
Beta0.43
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEODavid Atkins
Employees23
SectorHealthcare
IndustryMedical - Diagnostics & Research
IPO Date2017-12-06
Websiterhythmbio.com
Bio21 Institute
Parkville, VIC 3010
AU
Parkville, VIC 3010
AU
61 3 8256 2880
About Rhythm Biosciences Limited
Rhythm Biosciences Limited functions as a forward-thinking enterprise focused on predictive cancer diagnostics, active across both Australian and global territories. The company's core operations involve the creation, advancement, and market introduction of cutting-edge medical diagnostic technologies. A key innovation is ColoSTAT, their specialized blood test designed for the prompt and reliable identification of colorectal cancer. Established in 2017, the firm's main offices are located in Parkville, Australia.
Latest News
No recent news
Recent Insider Trades
No insider trades found